- Home
- OMF vs JAZZ Comparison
OMF vs JAZZ Comparison
Compare OMF & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMF
- JAZZ
- Stock Information
- Founded
- OMF 1920
- JAZZ 2003
- Country
- OMF United States
- JAZZ Ireland
- Employees
- OMF N/A
- JAZZ N/A
- Industry
- OMF Finance: Consumer Services
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- OMF Finance
- JAZZ Health Care
- Exchange
- OMF Nasdaq
- JAZZ Nasdaq
- Market Cap
- OMF 6.3B
- JAZZ 6.7B
- IPO Year
- OMF 2013
- JAZZ 2007
- Fundamental
- Price
- OMF $54.11
- JAZZ $107.51
- Analyst Decision
- OMF Buy
- JAZZ Strong Buy
- Analyst Count
- OMF 10
- JAZZ 12
- Target Price
- OMF $57.40
- JAZZ $183.08
- AVG Volume (30 Days)
- OMF 829.1K
- JAZZ 730.8K
- Earning Date
- OMF 07-30-2025
- JAZZ 07-30-2025
- Dividend Yield
- OMF 7.69%
- JAZZ N/A
- EPS Growth
- OMF N/A
- JAZZ 49.21
- EPS
- OMF 4.73
- JAZZ 7.51
- Revenue
- OMF $2,583,000,000.00
- JAZZ $4,064,808,000.00
- Revenue This Year
- OMF $74.69
- JAZZ $6.05
- Revenue Next Year
- OMF $7.73
- JAZZ $4.68
- P/E Ratio
- OMF $11.43
- JAZZ $14.35
- Revenue Growth
- OMF 0.94
- JAZZ 5.76
- 52 Week Low
- OMF $38.00
- JAZZ $95.49
- 52 Week High
- OMF $58.90
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- OMF 60.98
- JAZZ 45.65
- Support Level
- OMF $52.27
- JAZZ $106.56
- Resistance Level
- OMF $53.35
- JAZZ $109.43
- Average True Range (ATR)
- OMF 1.10
- JAZZ 2.66
- MACD
- OMF -0.01
- JAZZ -0.16
- Stochastic Oscillator
- OMF 91.46
- JAZZ 12.27
About OMF OneMain Holdings Inc.
OneMain Holdings Inc is a consumer finance company providing loan products to customers through its branch network and the internet. The company provides personal loan products; offers credit cards; offers optional credit insurance and others; offers a customer-focused financial wellness program, and acquisitions and dispositions of assets and businesses. It provides origination, underwriting, and servicing of personal loans to non-prime customers. The company's reportable segment is Consumer and Insurance. The main source of revenue is net interest income.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.